Belotero Volume (+): the exact 2026 FDA midface approval

FDA approved Belotero Volume (+) Lidocaine on May 19, 2026 for deep subcutaneous or supraperiosteal injection to improve midface volume deficit or contour deficiency in adults at least 22 years old. Its pivotal comparison met a prespecified noninferiority standard against another approved filler; it did not show that Belotero Volume is superior to all cheek fillers or suitable for every facial area.¹²

“Belotero” is a product family, not one blanket indication. The Volume (+) Lidocaine record must be read on its own. An approval for midface volume does not automatically cover earlobes, under-eyes, temples, or a generic “full-face lift.” It also differs from the broader cheek implant versus filler versus fat-grafting decision, which compares modalities rather than this named product’s FDA evidence.

The approval has a precise anatomical and age scope

FDA’s original PMA names a hyaluronic-acid filler containing lidocaine for deep midface volume or contour correction in adults 22 and older. “Deep subcutaneous or supraperiosteal” specifies placement in the authorized use; it is not a how-to instruction for a reader. The original approval date is May 19, 2026. Later listed PMA supplements concern manufacturing or assay matters and do not, in the reviewed records, broaden the original anatomy.¹

The patient label includes product-specific contraindications, including certain severe allergies and lidocaine-related allergy concerns. It also warns of rare but serious harm from unintended injection into a blood vessel, including tissue injury, blindness, or stroke. A consultation should review that actual patient guide and the practice’s complication response, rather than describing the product only as a “natural HA gel.”³

What the pivotal study did—and did not—show

The FDA effectiveness summary describes a randomized comparison with 202 assigned subjects and a blinded live evaluator. At 12 weeks, the mean improvement on the midface fullness scale was 1.60 points for Belotero Volume and 1.53 for the comparator in the reported analysis. The study met its prespecified noninferiority margin. This means the analysis supported that it was not worse than the comparator by the chosen margin; it is not a demonstration of superiority, permanent volume, or the same result for every face.²

Ask the provider to name the exact product, explain the midface goal, show the FDA patient labeling, and clarify whether any proposed site falls outside this approval. If a second product is offered, compare the two product labels rather than relying on a brand slogan. Compare dermal filler providers to find a consultation where the named product, intended anatomy, and emergency plan can be discussed together.

What noninferiority means in this filing

The pivotal trial’s primary comparison asked whether the Belotero Volume result fell within a predefined margin of the comparator at a specified follow-up, as judged on a midface fullness scale. Meeting that standard supports the FDA effectiveness finding for the labeled use. It is not a ranking across all fillers, a guarantee of long-term persistence, or proof that the new product looks more natural. Those claims would require different endpoints and comparisons.²

The study’s 202 randomized participants and 12-week primary endpoint should accompany any quoted result. A before-and-after photograph may illustrate an outcome, but the evaluator scale and comparator show what was actually tested. A high responder proportion within a selected trial group is not a forecast that the same proportion of every clinic’s clients will be satisfied. A provider should identify whether its claim comes from the PMA study or from its own experience; those evidence categories are not interchangeable.²

Approval is product-specific, and so is the safety record

Belotero Volume (+) Lidocaine has an HA-based composition, but that shared material does not give it every other HA product’s anatomical approval. If a practice proposes a different Belotero family member, ask for that product’s own indication and patient guide. If it proposes an off-label site, the FDA approval for the midface should not be used as if it covered that new location.¹³

The patient labeling’s intravascular-injection warning makes the practice’s response pathway an essential part of the consultation. Ask who identifies a problem during or after the procedure. Seek immediate medical attention for unusual pain, vision changes, white, gray, or blue skin near the injection site, or stroke-like signs during or shortly after filler injection. These are FDA’s urgent warning signs, not symptoms to monitor until a routine follow-up.³⁴ An FDA approval supports the named use under its evidence, not a guarantee against complications or an endorsement of any particular provider. The Juvederm-versus-Restylane label guide can help readers compare named records rather than treating brand families as single products.